戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1                  Previously untreated patients with ES SCLC were randomly assigned in a 1:1 fashion to receive carboplati
2 ged Percutaneous Coronary Intervention) trial, 584 patients were randomly assigned in a 1:1 manner to 1S-PCI or MS-PCI.
3     Enrolled patients received surgery for GPi DBS and then were randomly assigned in a 1:1 ratio (computer-generated pai
4       Eligible patients with native papilla undergoing ERCP were randomly assigned in a 1:1 ratio (with a computer-genera
5                                                    Patients were randomly assigned in a 1:1 ratio and were stratified acc
6                                              Eligible women were randomly assigned in a 1:1 ratio by central computer all
7 on pirfenidone (at least 1602 mg/day for 8 weeks or longer) were randomly assigned in a 1:1 ratio by interactive voice re
8                                                       Girls were randomly assigned in a 1:1 ratio to 1 of 2 groups within
9 ipants from Ontario, Canada, experiencing recurrence of CDI were randomly assigned in a 1:1 ratio to 14 days of oral vanc
10                                       In period 1, patients were randomly assigned in a 1:1 ratio to 40 mg of adalimumab
11 December 2007, enrolled 168 patients with high-risk PCa who were randomly assigned in a 1:1 ratio to conventional (80 Gy
12                                                    Patients were randomly assigned in a 1:1 ratio to either 10 sessions o
13                                                    Patients were randomly assigned in a 1:1 ratio to receive adalimumab (
14                                                    Patients were randomly assigned in a 1:1 ratio to receive ATG or not r
15 s, patients with ST-segment elevation myocardial infarction were randomly assigned in a 1:1 ratio to receive EES or BMS.
16                                                    Patients were randomly assigned in a 1:1 ratio to receive either 100 m
17                                           Eligible patients were randomly assigned in a 1:1 ratio to receive either 400 m
18                                           Eligible patients were randomly assigned in a 1:1 ratio to receive either CDDP
19 breast cancer receiving treatment with aromatase inhibitors were randomly assigned in a 1:1 ratio to receive either denos
20                  In the phase 2 part of the study, patients were randomly assigned in a 1:1 ratio to receive either olara
21                                Eligible patients of any age were randomly assigned in a 1:1 ratio to receive either the c
22  previously received a regimen containing an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive either the n
23 previously received a DAA regimen but not an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive sofosbuvir-v
24 th an estimated GFR of 25 to 44 ml per minute per 1.73 m(2) were randomly assigned in a 1:1 ratio to receive tolvaptan or
25                                                    Patients were randomly assigned in a 1:1 ratio to SABR or lobectomy wi
26 0 to 1), stratified by histology (epithelioid or biphasic), were randomly assigned in a 1:1 ratio to up to six cycles of
27          Following 2 weeks of open placebo run-in, patients were randomly assigned in a 1:1 ratio with a block size of 4
28 n, aged 16 years or older and with newly diagnosed epilepsy were randomly assigned in a 1:1 ratio, via a computer-generat
29                                                Participants were randomly assigned in a 1:1:1 ratio to once-daily placebo
30 icin-sensitive, previously untreated pulmonary tuberculosis were randomly assigned in a 1:1:1:1:2 ratio to receive (all o
31                                           Eligible patients were randomly assigned in a 2:1 ratio by an interactive voice
32                                              These patients were randomly assigned in a 2:1 ratio to receive afatinib or
33                                                    Patients were randomly assigned in a 2:1 ratio to receive alirocumab (
34                               Previously untreated patients were randomly assigned in a 2:1 ratio to receive either 12 we
35      Patients who were taking a stable dose of methotrexate were randomly assigned in a 2:1 ratio to receive either adali
36 nts with hereditary angioedema with C1 inhibitor deficiency were randomly assigned in a 2:1 ratio to receive either lanad
37 nd non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2:1 ratio to receive niraparib (3
38                                                    Patients were randomly assigned in a 2:1 ratio to receive trabectedin
39 superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB o
40  2-4 years in urban Kamalapur and rural Matlab, Bangladesh, were randomly assigned in a 2:1 ratio, according to a compute
41                                     In our study, 1,099 men were randomly assigned in a 2:1 schedule to receive orteronel
42 eatment-naive patients with pulmonary arterial hypertension were randomly assigned in a 2:1:1 ratio and received combinat
43                                                    Patients were randomly assigned in a 2:2:1 ratio to receive one of the
44                                        In group 2, patients were randomly assigned in a 3:1 ratio to receive 1200 million
45 second-generation healthy women of Mexican descent (n = 53) were randomly assigned in a crossover design to consume a Mex
46 risk patients receiving HPS followed in a tertiary HPS unit were randomly assigned in a double-blinded, placebo-controlle
47 agnetic resonance imaging (MRI)-documented lacunar infarcts were randomly assigned in a factorial design to target levels
48                                                    Patients were randomly assigned in a one-to-one ratio to GV or GP.
49 in the upper third of the albumin-to-creatinine ratios; 443 were randomly assigned in a placebo-controlled trial of an AC
50                 In the second cohort, participants with CIC were randomly assigned in a study across four centres with si

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。